Paroxetine Hydrochloride Tablet, Film Coated, Extended Release
FDA Label NDC 62175-472

52 label sections · Submitted to the FDA by Lannett Company, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Lannett Company, Llc for the product Paroxetine Hydrochloride (NDC 62175-472). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: suicidal thoughts and behaviors, 1 indications and usage, 2.1 screen for bipolar disorder prior to starting paroxetine, 2.2 important administration instructions, 2.3 dosage in patients with major depressive disorder, panic disorder, and social anxiety disorder, 2.4 dosage in patients with premenstrual dysphoric disorder, 2.5 recommended dosage in geriatric patients, patients with severe renal impairment and patients with severe hepatic impairment, 2.6 switching patients to or from a monoamine oxidase inhibitor antidepressant, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.